In what has been described as one of the slowest, closed-window public markets in recent years, Acelyrin Inc. priced an upsized IPO, raising $540 million, the fifth highest amount for a U.S. IPO by a traditional biopharma company to date. Despite industry IPOs raising only $628 million throughout the first four months of 2023 – the lowest amount in 10 years, Acelyrin’s IPO suggests that there is still a strong investor appetite ready and waiting for innovative technologies with solid data. Read More
University of Sydney spinout Kinoxis Therapeutics Pty announced a partnership and licensing agreement with Boehringer Ingelheim GmbH to develop first-in-class oxytocin-targeting precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric disorders. Under the terms of the agreement, Kinoxis will receive an up-front payment and research support payments and is eligible for research, preclinical, clinical, regulatory and commercial milestones of up to AU$266 million (US$181 million), in addition to sales-based royalties. Read More
With the COVID-19 public health emergency ending in the U.S. next week, Congress is looking to use the lessons learned from the pandemic to draft a new iteration of the Pandemic and All-Hazards Preparedness Act to ensure the country is better prepared for the next pandemic. Read More
Fibrogen Inc. and its co-development partners for roxadustat, Astrazeneca plc and Astellas Pharma Inc., were dealt a major blow May 5 as the oral hypoxia-inducible factor prolyl hydroxylase inhibitor failed to meet its primary efficacy endpoint in a phase III trial in patients with anemia caused by transfusion-dependent lower-risk myelodysplastic syndromes (MDS). Read More
The U.S. Inflation Reduction Act (IRA) may look like domestic affair, but the drug price controls it is bringing in are set to impact the biopharma sector across the globe. Read More
Please take a few minutes to fill out this short survey to help us provide you with the best possible source of news. Customer feedback is critical so that we can make BioWorld an even more useful and valuable component of your daily workflow. We want to continue to evolve to serve you. The survey should take less than 5 minutes. You can click through to the questions here. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alphyn, Alvotech, Beckley, Boan, Endogena, Immunic, Pieris, Scilex, Sellas, Soleno, Soligenix, Sound, Trellis, Visus. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adagene, Amphista, Astrazeneca, Bicycle, Biomed, Bristol, Concentra, Exelixis, Jounce, Neuraxpharm, Quince, Selecta, Silence, Soleno, Transgene, XNK. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Gilead, Optinose, Regeneron, Sanofi, Tonix, Valeo, Vertex, Xortx. Read More
